Pharmaceuticals Search Engine [selected websites]

Tuesday, June 22, 2010

Rhenovia's Epilepsy Program for the Optimization of Antiepileptic Drug Discovery & Development of Pharmaceutical and Biotechnology Companies

 Rhenovia Pharma2 June 2010 - Official Launch of Rhenovia's Epilepsy Program for the Optimization of Antiepileptic Drug Discovery & Development of Pharmaceutical and Biotechnology Companies...

...official launch of a collaborative project - cluster RHENEPI "Platform of neuronal modeling for the discovery and validation of drug treatments for Epilepsy"

This three-year project, of a total budget of 2.5 million euros, labeled cluster of Drug Innovation Alsace Bio Valley and competitiveness cluster Lyon Biopôle was obtained under the 9th call for projects launched by the Directorate General Competitiveness of Industry and Services of the French Ministry of Economy, Industry and Employment for funding from the Single Interministerial Fund (FUI).
The project RHENEPI lead by Rhenovia Pharma brings together four partners: two industrial partners, Rhenovia, a biotechnology company located in Mulhouse and SynapCell, a biotech company from Grenoble, and two academic partners: the research team of Dr. Antoine Depaulis Grenoble Neurosciences Institute (GIN) and Dr. Laurent Fagni, Institute of Functional Genomics (IGF) in Montpellier... Rhenovia Pharma's News -

Rhenovia Pharma's General Presentation

Rhenovia Pharma is a new R&D pharmaceutical and biotechnology company created on May 3, 2007.
It is headquartered at Mulhouse, 20c rue de chemnitz, France.
It has been founded by an international team highly committed to find new solutions to treat Alzheimer's disease (AD) and other diseases of the nervous system (NS).
Rhenovia has the legal form of an SAS. At present, it is funded by the founders, the team and business angels.
Core Activity: Biosimulation for brain diseases
Biosimulation consists in the use of computational models that provide a dynamic and quantitative description of a number of biological, pathological, and pharmacokinetic processes in order to understand complex biological processes. Biosimulation is particularly appropriate for use in CNS disease research. Unmet medical needs in this field, especially for Alzheimer's disease, are mostly due to the fact that all brain pathologies are extremely complex, multifactorial and dynamic... Rhenovia Pharma's General Presentation -

SynapCell
About SynapCell

SynapCell is a preclinical Contract Research Organization which provides translational solutions to evaluate the therapeutic potential of CNS drug candidates in epilepsy. SynapCell provides customized solutions which cover the entire range of customers needs, from early steps to the final answer... SynapCell company -